Search results for "Type 2 diabetes mellitus"

showing 10 items of 198 documents

Endothelial GLP-1 (Glucagon-Like Peptide 1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension

2019

Supplemental Digital Content is available in the text.

0301 basic medicineMalemedicine.medical_specialtyhypertensionBlotting WesternInflammationBlood Pressure030204 cardiovascular system & hematologyangiotensin IImedicine.disease_causeGlucagon-Like Peptide-1 Receptor1005403 medical and health sciencesMice0302 clinical medicine10030Internal medicinemedicineoxidative stressAnimalsHypoglycemic AgentsReceptor10111Cells CulturedMice KnockoutliraglutideLiraglutidebusiness.industryBasic SciencesType 2 Diabetes MellitusEndothelial CellsAtherosclerosisGlucagon-like peptide-1Angiotensin II3. Good healthMice Inbred C57BLDisease Models Animal030104 developmental biologyEndocrinology10040inflammationComputingMethodologies_DOCUMENTANDTEXTPROCESSINGRNAmedicine.symptomCardiology and Cardiovascular Medicinebusiness10024Oxidative stressmedicine.drug
researchProduct

Sucralose and Cardiometabolic Health: Current Understanding from Receptors to Clinical Investigations

2021

International audience; The excess consumption of added sugar is consistently found to be associated with weight gain, and a higher risk of type 2 diabetes mellitus, coronary heart disease, and stroke. In an effort to reduce the risk of cardiometabolic disease, sugar is frequently replaced by low- and null-calorie sweeteners (LCSs). Alarmingly, though, emerging evidence indicates that the consumption of LCSs is associated with an increase in cardiovascular mortality risk that is amplified in those who are overweight or obese. Sucralose, a null-caloric high-intensity sweetener, is the most commonly used LCS worldwide, which is regularly consumed by healthy individuals and patients with metab…

0301 basic medicineNon-Nutritive SweetenersSucroseSucraloseCalorieglucose metabolismMedicine (miscellaneous)030209 endocrinology & metabolismReviewOverweightGut floraAdded sugar03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEnvironmental healthmedicineHumansGlucose homeostasis2. Zero hungerNutrition and Dieteticsbiologybusiness.industrysweet and bitter taste receptorType 2 Diabetes Mellitussucralosetaste signaling cascadecardiovascular healthbiology.organism_classification3. Good health030104 developmental biologyDiabetes Mellitus Type 2chemistryCardiovascular Diseaseslow-calorie sweetenermedicine.symptombusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionWeight gainFood ScienceAdvances in Nutrition
researchProduct

A Systematic Study of Dysregulated MicroRNA in Type 2 Diabetes Mellitus

2017

MicroRNAs (miRNAs) are small noncoding RNAs that modulate the cellular transcriptome at the post-transcriptional level. miRNA plays important roles in different disease manifestation, including type 2 diabetes mellitus (T2DM). Many studies have characterized the changes of miRNAs in T2DM, a complex systematic disease; however, few studies have integrated these findings and explored the functional effects of the dysregulated miRNAs identified. To investigate the involvement of miRNAs in T2DM, we obtained and analyzed all relevant studies published prior to 18 October 2016 from various literature databases. From 59 independent studies that met the inclusion criteria, we identified 158 dysregu…

0301 basic medicineSystematic surveytype 2 diabetes mellitussystematic study030209 endocrinology & metabolismDiseaseBioinformaticsCatalysisArticleInorganic ChemistryTranscriptomelcsh:Chemistry03 medical and health sciences0302 clinical medicineDiabetes mellitusmiRNA-mRNA interaction networkmicroRNAmedicineHumansGene Regulatory NetworksRNA MessengerPhysical and Theoretical Chemistry10. No inequalityMolecular Biologylcsh:QH301-705.5SpectroscopyAdipocytokine Signaling PathwaymicroRNA; type 2 diabetes mellitus; miRNA-mRNA interaction network; systematic studymicroRNAbusiness.industryGene Expression ProfilingOrganic ChemistryType 2 Diabetes MellitusGeneral Medicinemedicine.diseaseComputer Science ApplicationsMicroRNAs030104 developmental biologyDiabetes Mellitus Type 2Gene Expression Regulationlcsh:Biology (General)lcsh:QD1-999Organ SpecificityRNA InterferenceDisease manifestationbusinessTranscriptomeSignal TransductionInternational Journal of Molecular Sciences
researchProduct

Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders

2019

Thyroid dysfunction and diabetes mellitus are closely linked. Several studies have documented the increased prevalence of thyroid disorders in patients with diabetes mellitus and vice versa. This review critically discusses the different underlying mechanisms linking type 1 and 2 diabetes and thyroid dysfunction to demonstrate that the association of these two common disorders is unlikely a simple coincidence. We assess the current state of knowledge on the central and peripheral control of thyroid hormone on food intake and glucose and lipid metabolism in target tissues (such as liver, white and brown adipose tissue, pancreatic b cells, and skeletal muscle) to explain the mechanism linking…

0301 basic medicineendocrine system diseasesEndocrinology Diabetes and MetabolismReviews030209 endocrinology & metabolismType 2 diabetesBioinformatics03 medical and health sciences0302 clinical medicineEndocrinologyHypothyroidismDiabetes mellitusmedicineAnimalsHumansSubclinical infectionType 1 diabetesbusiness.industryThyroidmedicine.diseaseThyroid DiseasesDiabetes Mellitus Type 1030104 developmental biologymedicine.anatomical_structureDiabetes Mellitus Type 2Metabolic control analysisMetabolic syndromeHyperthyroidism Hypothyroidism type 1 diabetes mellitus type 2 diabetes mellitus metabolic syndrome pregnancy guidelinesbusinessHormoneEndocrine Reviews
researchProduct

Mitochondria, the NLRP3 Inflammasome, and Sirtuins in Type 2 Diabetes: New Therapeutic TargetsReviewing Editors:Markus Bachschmid, Dylan Burger, Vitt…

2018

Abstract Significance: Type 2 diabetes mellitus and hyperglycemia can lead to the development of comorbidities such as atherosclerosis and microvascular/macrovascular complications. Both type 2 dia...

0301 basic medicineendocrine system diseasesPhysiologyClinical BiochemistryType 2 diabetesMitochondrionBioinformaticsmedicine.disease_causeBiochemistry03 medical and health sciencesMedicineMolecular BiologyGeneral Environmental Sciencebusiness.industryfungifood and beveragesnutritional and metabolic diseasesType 2 Diabetes MellitusInflammasomeCell Biologymedicine.disease030104 developmental biologyGeneral Earth and Planetary SciencesbusinessOxidative stressmedicine.drugAntioxidants & Redox Signaling
researchProduct

Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors

2020

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors are so called “incretin-based therapies” (IBTs) that represent innovative therapeutic approaches and are commonly used in clinical practice for the treatment of type 2 diabetes mellitus (T2DM). The cardiovascular outcome trials (CVOTs) have provided useful information that has helped to shape changes in clinical practice guidelines for the management of T2DM. At the same time, the mechanisms that may explain the nonglycemic and cardiovascular (CV) benefits of these medications are still being explored. A summary of the main findings from CVOTs performed to-date with particular emphasis on vari…

0301 basic medicineendocrine systemmedicine.medical_specialtyDipeptidyl Peptidase 4Endocrinology Diabetes and MetabolismIncretin030209 endocrinology & metabolismClass effectBody weightCardiovascular SystemIncretinsGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineType 2 diabetes mellitusmedicineAnimalsHumansIntensive care medicineGlucagon-like peptide 1 receptorDipeptidyl-Peptidase IV Inhibitorsbusiness.industryDPP-4 Inhibitorsdigestive oral and skin physiologyType 2 Diabetes MellitusCardiovascular riskDPP4- inhibitorClinical Practice030104 developmental biologyCardiovascular DiseasesGlucagon-like peptide 1 receptor agonistbusinessCardiovascular outcomesMetabolism
researchProduct

Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.

2019

The Collaborative Working Group “Noma Project Team”.

0301 basic medicinelcsh:Immunologic diseases. Allergycritical limb ischemiaCell typecost-effectivecell-based therapyImmunologyBioinformaticsCell therapy03 medical and health sciences0302 clinical medicineImmunology and AllergyMedicineOriginal Researchclinical trialsdiabetesbusiness.industryMesenchymal stem cellType 2 Diabetes MellitusCritical limb ischemiacellular medicamentsClinical trial030104 developmental biologyStem cellmedicine.symptombusinesslcsh:RC581-607030215 immunologyAdult stem cell
researchProduct

Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect

2020

Liraglutide has shown favourable effects on several cardiometabolic risk factors, beyond glucose control. MicroRNAs (miRNAs) regulate gene expression, resulting in post-transcriptional modifications of cell response and function. Specific miRNAs, including miRNA-27b, miRNA-130a, and miRNA-210, play a role in cardiometabolic disease. We aimed to determine the effect of liraglutide on the serum levels of miRNA-27b, miRNA-130a and miRNA-210. Twenty-five subjects with type-2 diabetes mellitus (T2DM), na&iuml

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolismlcsh:QR1-502IncretinType 2 diabetestype-2 diabetes030204 cardiovascular system & hematologyBiochemistryArticlelcsh:Microbiologyliraglutide; microRNAs; type-2 diabetes; cardiometabolic risk; epigenetic03 medical and health sciences0302 clinical medicineInterquartile rangeDiabetes mellitusInternal medicinecardiometabolic riskMedicineMolecular Biologyliraglutidebusiness.industryLiraglutideType 2 Diabetes MellitusMicroRNAmedicine.diseaseMetforminmicroRNAs030104 developmental biologyEndocrinologybusinessHomeostasisepigeneticmedicine.drugMetabolites
researchProduct

Mitochondrial DNA Haplogroup JT is Related to Impaired Glycaemic Control and Renal Function in Type 2 Diabetic Patients

2018

The association between mitochondrial DNA (mtDNA) haplogroup and risk of type 2 diabetes (T2D) is undetermined and controversial. This study aims to evaluate the impact of the main mtDNA haplogroups on glycaemic control and renal function in a Spanish population of 303 T2D patients and 153 healthy controls. Anthropometrical and metabolic parameters were assessed and mtDNA haplogroup was determined in each individual. Distribution of the different haplogroups was similar in diabetic and healthy populations and, as expected, T2D patients showed poorer glycaemic control and renal function than controls. T2D patients belonging to the JT haplogroup (polymorphism m.4216T&gt

0301 basic medicinemedicine.medical_specialtyendocrine system diseasesgenetic structurestype 2 diabetes mellituslcsh:MedicineRenal functionType 2 diabetesArticleHaplogroupNephropathyDiabetic nephropathy03 medical and health scienceschemistry.chemical_compoundInternal medicineMedicineCreatininebusiness.industrymtDNAlcsh:Rmitochondrial haplogroupType 2 Diabetes Mellitusnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseeye diseaseshumanities030104 developmental biologyEndocrinologychemistryglycemic controlnephropathybusinessHuman mitochondrial DNA haplogroup
researchProduct

Srebf2 Locus Overexpression Reduces Body Weight, Total Cholesterol and Glucose Levels in Mice Fed with Two Different Diets

2020

Macronutrients represent risk factors for hyperlipidemia or diabetes. Lipid alterations and type 2 diabetes mellitus are global health problems. Overexpression of sterol regulatory element-binding factor (Srebf2) in transgenic animals is linked to elevated cholesterol levels and diabetes development. We investigated the impact of increased Srebf2 locus expression and the effects of control and high-fat, high-sucrose (HFHS) diets on body weight, glucose and lipid metabolisms in transgenic mice (S-mice). Wild type (WT) and S-mice were fed with both diets for 16 weeks. Plasma glucose, insulin and lipids were assessed (n = 25). Immunostainings were performed in liver, pancreas and fat (N = 10).…

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatment030209 endocrinology & metabolismlcsh:TX341-641Carbohydrate metabolismtransgenic miceArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineAdipocyteDiabetes mellitusHyperlipidemialipid metabolismmedicinecarbohydrate metabolismhigh-sucrose diethigh-fatNutrition and DieteticsCholesterolInsulinType 2 Diabetes MellituscholesterolLipid metabolismmedicine.diseaselipoproteins030104 developmental biologyEndocrinologychemistrylipids (amino acids peptides and proteins)atherosclerosissterol regulatory element-binding protein 2 (SREBP-2)lcsh:Nutrition. Foods and food supplyFood ScienceNutrients
researchProduct